208 related articles for article (PubMed ID: 29035675)
1. Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics.
Li Z; Easton R
MAbs; 2018 Jan; 10(1):18-33. PubMed ID: 29035675
[TBL] [Abstract][Full Text] [Related]
2. Systematic Review of Device Parameters and Design of Studies Bridging Biologic-Device Combination Products Using Prefilled Syringes and Autoinjectors.
Hu P; Wang J; Florian J; Shatzer K; Stevens AM; Gertz J; Ji P; Huang SM; Zineh I; Wang YC
AAPS J; 2020 Feb; 22(2):52. PubMed ID: 32107671
[TBL] [Abstract][Full Text] [Related]
3. Patient-centric Comparability Assessment of Biopharmaceuticals.
Blümel M; Cordoba-Rodriguez R; Carroll JA; Beardsley RL; Maggio F; Wylie D; Tsang V; Ehrick R; Francq BG; Pohl T; Taktak S; Spasoff A; Morrison A; Albarghouthi M
J Pharm Sci; 2024 Jun; 113(6):1415-1425. PubMed ID: 38373591
[TBL] [Abstract][Full Text] [Related]
4. Human factors studies for injectable combination products: from planning to reporting.
Towns JK
PDA J Pharm Sci Technol; 2014; 68(4):347-61. PubMed ID: 25035257
[TBL] [Abstract][Full Text] [Related]
5. Design control considerations for biologic-device combination products.
Anderson D; Liu R; Anand Subramony J; Cammack J
Adv Drug Deliv Rev; 2017 Mar; 112():101-105. PubMed ID: 28088344
[TBL] [Abstract][Full Text] [Related]
6. Injectable
Bisht R; Nirmal S; Agrawal R; Jain GK; Nirmal J
J Drug Target; 2021 Jan; 29(1):46-59. PubMed ID: 32729731
[TBL] [Abstract][Full Text] [Related]
7. Generic drug device combination products: Regulatory and scientific considerations.
Choi SH; Wang Y; Conti DS; Raney SG; Delvadia R; Leboeuf AA; Witzmann K
Int J Pharm; 2018 Jun; 544(2):443-454. PubMed ID: 29170118
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective.
Zhuang Y; Chen D; Sharma A; Xu Z
AAPS J; 2018 Oct; 20(6):109. PubMed ID: 30324224
[TBL] [Abstract][Full Text] [Related]
10. Inhaled Biologics: From Preclinical to Product Approval.
Fathe K; Ferrati S; Moraga-Espinoza D; Yazdi A; Smyth HD
Curr Pharm Des; 2016; 22(17):2501-21. PubMed ID: 26861725
[TBL] [Abstract][Full Text] [Related]
11. A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems.
Jenke D; Carlson T
PDA J Pharm Sci Technol; 2014; 68(5):407-55. PubMed ID: 25336416
[TBL] [Abstract][Full Text] [Related]
12. Approaches to Quality Risk Management When Using Single-Use Systems in the Manufacture of Biologics.
Ishii-Watabe A; Hirose A; Katori N; Hashii N; Arai S; Awatsu H; Eiza A; Hara Y; Hattori H; Inoue T; Isono T; Iwakura M; Kajihara D; Kasahara N; Matsuda H; Murakami S; Nakagawa T; Okumura T; Omasa T; Takuma S; Terashima I; Tsukahara M; Tsutsui M; Yano T; Kawasaki N
AAPS PharmSciTech; 2015 Oct; 16(5):993-1001. PubMed ID: 26288941
[TBL] [Abstract][Full Text] [Related]
13. Overview of drug product development.
Narayan P
Curr Protoc Pharmacol; 2011 Dec; Chapter 7():Unit 7.3.1-29. PubMed ID: 22147349
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies.
Putnam WS; Prabhu S; Zheng Y; Subramanyam M; Wang YM
Trends Biotechnol; 2010 Oct; 28(10):509-16. PubMed ID: 20691488
[TBL] [Abstract][Full Text] [Related]
15. The challenge of follow-on biologics for treatment of multiple sclerosis.
Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS
Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456
[TBL] [Abstract][Full Text] [Related]
16. Product Development, Manufacturing, and Packaging of Solid Dosage Forms Under QbD and PAT Paradigm: DOE Case Studies for Industrial Applications.
Singh BN
AAPS PharmSciTech; 2019 Sep; 20(8):313. PubMed ID: 31529232
[TBL] [Abstract][Full Text] [Related]
17. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
[TBL] [Abstract][Full Text] [Related]
18. Managing unexpected events in the manufacturing of biologic medicines.
Grampp G; Ramanan S
BioDrugs; 2013 Aug; 27(4):305-16. PubMed ID: 23529766
[TBL] [Abstract][Full Text] [Related]
19. Risk-Based Quality and Compliance Management in Clinical Trials with Combination Products in Changing Global Regulatory Environment.
Kaliaev AO; Malikova MA
Ther Innov Regul Sci; 2020 Jul; 54(4):803-813. PubMed ID: 32557305
[TBL] [Abstract][Full Text] [Related]
20. Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics.
Ait-Oudhia S; Wang YM; Dosne AG; Roy A; Jin JY; Shen J; Kagan L; Musuamba FT; Zhang L; Kijima S; Gastonguay MR; Ouellet D
Clin Pharmacol Ther; 2024 Mar; 115(3):412-421. PubMed ID: 38069528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
